Bangalore, April 25, 2014 – Biocon Ltd., Asia’s premier biotechnology company, announced that the Board of Directors of the Company, in their meeting today, have approved the induction of Dr. Arun Chandavarkar, on to the board of Biocon Limited. He has also been appointed as Chief Executive Officer and Joint Managing Director.
Welcoming Arun on the Board, Kiran Mazumdar-Shaw, CMD, Biocon, said, “I am extremely happy to have Arun join the Board of Directors and take on the mantle of CEO & Joint MD. Arun has been a core member of the leadership team at Biocon and has worked very closely with me over the last 24 years. He has played a pivotal role in the evolution of Biocon and I am confident that, in his new role, he will build immense value for Biocon and its stakeholders.”
Dr. Arun Chandavarkar, CEO & Joint MD, Biocon, said, “I am delighted and honoured to join the Board of Biocon. These are exciting times and I look forward to steering the Company to the next level.”
Dr. Arun Chandavarkar has a B. Tech from IIT, Bombay and earned his Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology, Cambridge, USA
Dr. Chandavarkar has been the Chief Operating Officer of Biocon since 2006. He joined Biocon as General Manager – Operations in 1990. Under his leadership, Biocon has established expertise in diverse technology platforms spanning microbial fermentation, cell culture, chemical synthesis and purification to develop a wide range of products from specialty enzymes to active pharmaceutical ingredients to recombinant therapeutic proteins. BWI
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…